Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201, a B-Cell Immunotherapy as Monotherapy or in Combination With Atezolizumab With or Without Chemotherapy, in Adults With Non- Small Cell Lung Cancer (IMPrinter)

NCT04432207 is registered in ClinicalTrials.gov with Imugene Limited as lead sponsor.

NCT NCT04432207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201, a B-Cell Immunotherapy as Monotherapy or in Combination With Atezolizumab With or Without Chemotherapy, in Adults With Non- Small Cell Lung Cancer (IMPrinter)
Lead sponsor
Imugene Limited
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2020
Completion date
November 7, 2024
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma lung, large cell carcinoma lung, non small cell lung cancer, non small cell lung cancer stage iiib, non-small cell lung cancer stage iv, squamous non-small-cell lung cancer